Relation Between Severity of *Helicobacter Pylori* Induced Gastritis and Glycemic Control in Egyptian Male Patients with Type-2 Diabetes Mellitus

Khaled Aly Abdelaty¹, Ayman Mohammed Shamseya¹, Marwa Ahmed Meheissen² and Marwa Ibrahim³

¹Department of Internal Medicine and Gastroenterology, Alexandria University, Egypt.
²Department of Microbiology, Alexandria University, Egypt.
³Department of Tropical medicine, Alexandria University, Egypt.

*Correspondence:* Marwa Ibrahim, Department of tropical medicine, Alexandria University, Egypt, E-mail: marwaibrahim90@yahoo.com.

Received: 24 February 2019; Accepted: 17 March 2019

**ABSTRACT**

**Background:** Helicobacter pylori (HP) infection is the most common infection in the world. It was associated with many gastrointestinal and extra-gastrointestinal diseases. There was evidence of strong association between *H. pylori* infection and Diabetes Mellitus, especially Type 2 DM.

**Objectives:** The aim of our study was to investigate the relationship between severity of *Helicobacter Pylori* induced gastritis and glycemic control in patients with type 2 diabetes.

**Patients and methods:** Fifty type 2 diabetic male patients (mean age 47.50 ± 6.01 years) were admitted to gastroenterology unit of the Alexandria Main University Hospital for upper gastrointestinal endoscopy. Thirty of them are *H. pylori* positive (cases) and twenty were *H. pylori* negative (controls). Following data were collected from all patients: BMI, waist circumference, CBC, liver enzymes, urea, creatinine, Hemoglobin A1c level, fasting blood glucose. Also biopsy specimens were obtained to Diagnose *H. pylori* by rapid urease test and to assess severity of gastritis histopathologically by Updated Sydney Score.

**Result:** comparison between the two studied groups according to age, BMI, ESR, liver enzymes and creatinine showed no significant difference while hemoglobin, platete count, blood urea showed significant difference between the two groups. Although fasting blood glucose showed no statistically significant difference, Hemoglobin A1c showed significant difference between the two groups (p<0.001). There was a statistically significant relationship between hemoglobin A1c and the severity of *H. pylori* inflammation in cases group (p<0.001). Levels of Hb A1C were positively correlated with neutrophil infiltration, chronic inflammation, glandular atrophy and intestinal metaplasia in histopathology samples from cases group.

**Conclusions:** *Helicobacter Pylori* infection and severity of *H. pylori* induced gastritis correlate with higher levels of Hb A1C in type 2 diabetic patients.

**Keywords**

*Helicobacter Pylori*, Diabetes, Gastritis.

**Introduction**

*Helicobacter pylori* prevalence is worldwide, but it differs among countries and among populations in the same country [1]. Type 2 diabetes has a complex pathogenesis. Environmental factors are critical in its pathogenesis. It would be very valuable medically and economically to detect any treatable causes of this disease to delay or prevent its onset or delay its progression and complications. Glycated hemoglobin (HbA1c) Levels, which result from the non-enzymatic glycosylation of hemoglobin and reflect the integrated blood glucose levels during the previous 3-4 months, can be used to diagnose diabetis and to estimate diabetes prevalence and incidence [2]. Diabetic patients are more liable to infections and bacterial overgrowth in upper GIT. The interrelation between *H. pylori* infection and type 2 diabetes is still under investigtion.
Helicobacter pylori infection and diabetes mellitus have been shown in some studies but the relationship remains debatable [3].

Some biological mechanisms may explicate this relation. First, altered metabolism of glucose may generate chemical changes in the gastric mucosa that help to anchor H. pylori infection [4]. Second, gastric infection with H.pylori increases secretion of pro-inflammatory cytokines, leading to changes in the structure of insulin receptors, disrupting the interaction between insulin and its receptors [5].

Dyspepsia is a very common symptom in both diabetic patients and H. Pylori infected persons, despite the endoscopic examination for H. pylori diagnosis is invasive, expensive, and time consuming, it is very valuable in determining clinical prognosis on the basis of the localization of a lesion [6]. It is considered to be the “gold standard” diagnostic tool for diagnosing H. pylori infection [7]. We conducted this study to focus on the relation between H.pylori and the glycemic control in type 2 diabetic patients, and to link it to the degree of severity of H.pylori induced gastritis as studied on histopathological basis.

**Patients and methods**

The study included fifty male patients with type 2 DM divided into 2 groups; group A of 20 controls with negative results for helicobacter Pylori infection and group B with 30 cases with positive results of H. pylori. We excluded age< 40 years, those who received previous anti-helicobacter treatment, Patients with uncontrolled hypertension, Patients with metabolic syndrome (waist circumference is more than 102 cm), those with liver or renal disease, and smokers.

Patients were selected from those admitted to the gastro-enterology & endoscopy unit of internal medicine department, Alexandria University for gastro-duodenoscopy after approval of the medical ethical committee and an informed written consent from all the patients enrolled in the study was taken.

In the present study all patients were evaluated for BMI and waist circumference to exclude those with metabolic syndrome. Routine lab tests (CBC, urea, creatinine, liver enzymes, ESR,) were done,. Lipid profile including total cholesterol, triglycerides, LDL cholesterol and HDL cholesterol were compared in both groups [8]. Hemoglobin A1c levels were measured by using high-performance liquid chromatography method in group A and B [9].

Endoscopic gastric mucosal biopsies were obtained by skilled endoscopist. Gastric mucosal biopsies were taken from the antrum, corpus and incisura angularis (five specimens) to make proper diagnosis of Helicobacter Pylori infection in case of patchy distribution. Histo-pathological grading according to Updated Sydney Score was done using both hematoxylin and Gimsa stain [10]. And one more antral specimen for identification of H. pylori by rapid urease test. Rapid urease test was considered positive when the colour of gel converts to Pink or red within 24 hours [11].

Statistical analyses used were; student t-test, F-test (ANOVA), Mann Whitney test, Kruskal Wallis test and Spearman coefficient [12].

**Result**

In our study, age of the study groups and body mass index (BMI) showed no statistically significant difference with P value 0.074 and 0.163 respectively.

Our results showed that there was no statistically significant difference between patients’ group and the control group as regard fasting blood glucose (P value=0.070). We found that Mean HbA1c among diabetics with H. pylori infection was significantly greater than H. pylori-negative diabetics (9.32 ± 1.15% and 7.50 ± 0.63% respectively with P value <0.001).

![Figure 1: Comparison between the two studied](image-url)
Discussion

Patients with diabetes mellitus are often affected by chronic infections. Many studies have evaluated the prevalence of *H. pylori* infection in diabetic patients and the possible role of this condition in their metabolic control. Some studies found a higher prevalence of infection in diabetic patients and reduced glycemic control while others did not support any correlation between glycemic control and *H. pylori* infection [14].

All patients enrolled in our study were male patients. Most of the *Helicobacter pylori* related diseases are associated with male gender, the role of gender as a risk factor for *H. pylori* infection is still debated. Another study conducted by Catherine confirms the male predominance of *H. pylori* infection in adults as a global and homogeneous phenomenon [15].

In the present study, Comparison between the studied groups according to body mass index showed no significant difference. However, Perdichizzi et al. [16]. Determined higher BMI values and waist circumference measurements in HP (+) patients than in HP (-) patients. The present study is concordant with most of the world literature, where no significant correlation of fasting blood glucose with *Helicobacter pylori* status was reported [17].

We obtained similar results to Yu Chen et al as they found that HbA1c was higher in HP (+) diabetic patients than HP (-) ones. They also observed decrease in level of HB A1c and better glycemic control after HP eradication [18]. The present study provides evidences that *H. pylori* infection is associated with atherogenic lipid profile among patients with type 2 diabetes. *H. Pylori* infected group had statistically significant higher levels of total cholesterol, triglyceride and LDL than non-infected group.

Similarly, Bajaj S.et al reported that diabetic patients infected with *H. pylori* showed an atherogenic lipid profile characterized by an increase in LDL cholesterol or decreased HDL cholesterol compared to uninfected diabetic patients [19]. In the present study, we compared hemoglobin A1c with the degree of h.pylori chronic inflammation in studied groups of diabetic patients, and there was a statistically significant correlation between hemoglobin A1c and the severity of HP chronic inflammation in infected diabetic patients. Similarly, Hsieh et al found a significant association between chronic *H. pylori* infection and high levels of HbA1c levels as well as decreased insulin secretion in a Chinese population. They also found that the prevalence of type 2 diabetes was higher in subjects with chronic *H. pylori* infection than those without chronic *H. pylori* infection [20].

We also found that there was a statistically significant positive correlation between Hb A1c and the degree of intestinal metaplasia in our biopsy specimens of cases group. Ikeda et al obtained similar results as they found evidence that those with higher levels of HB A1C were more susceptible for intestinal metaplasia and gastric cancer [21]. Concerning the relationship between degree of gastritis as graded by updated Sydney score and the lipid profile, updated Sydney System score showed a statistically significant positive correlation with triglycerides levels. These results support the theory that *H. pylori* infection affects lipid metabolism and can increase the risk of atherosclerosis and cardiovascular events, while total cholesterol, LDL-C and HDL-C had no significant relation with the degree of gastritis. However, in a study by Kucukazman et al [22] they found moderate correlation between LDL-C levels and updated system score. This shows that LDL-C levels increase as *H. pylori* infection becomes more severe, and they demonstrated no difference in HDL-C and triglyceride levels between groups which contradicts with our study results.

Conclusion

Results of this work have shown that *Helicobacter Pylori* infection affects glycemic control in T2 DM patients as it is correlated to elevated levels of Hb A1c and atherogenic lipid profile so it plays a role in inducing atherosclerosis by elevating LDL cholesterol and triglycerides levels in diabetic patients. Severity of chronic inflammation, intestinal metaplasia, glandular atrophy, neutrophil infiltration and *H.pylori* density induced by HP infection are positively correlated to higher levels of Hb A1c and atherogenic lipid profile in diabetic patients.

References

1. Feldman RA. Epidemiologic observations and open questions about disease and infection caused by *helicobacter pylori*. In:
Achtman M, Suerbaum S. *Helicobacter pylori*: molecular and cellular biology. UK: Horizon Scientific Press. 2001. 29-51.

2. Buell C, Kermah D, Davidson MB. Utility of A1C for diabetes screening in the 1999 2004 NHANES population. Diabetes Care. 2007; 30: 2233-2235.

3. Zhou X, Zhang C, Wu J, et al. Association between *Helicobacter pylori* infection and diabetes mellitus: a meta-analysis of observational studies. Diabetes Res Clin Pract. 2013; 99: 200-208.

4. de Luis DA, de la Calle H, Roy G, et al. *Helicobacter pylori* infection and insulin-dependent diabetes mellitus. Diabetes Res Clin Pract. 1998; 39: 143-146.

5. Bener A, Micallef R, Afifi M, et al. Association between type 2 diabetes mellitus and *Helicobacter pylori* infection. Turk J Gastroenterol. 2007; 18: 225-229.

6. Vaira D, Gatta L, Ricci C, et al. Miglioli M. Review article: diagnosis of *Helicobacter pylori* infection. Aliment Pharmacol Ther. 2002; 16: 16-23.

7. Chey WD, Wong BC. Practice Practice American College of Gastroenterology guideline on the management of *Helicobacter pylori* infection. Am J Gastroenterol. 2007; 102: 1808-1825.

8. Kricka LJ. Principles of immunochemical techniques. In: Burtis CA, Ashwood ER (eds). Tietz fundamentals of clinical 6 chemistry. 5 th ed. Philadelphia: Wound B Saunders Company; 2001; 1: 177-194.

9. Holmes EW, Erşin C, Augustine GJ, et al. Analytic bias among certified methods for the measurement of hemoglobin A1c: a cause for concern? Am J Clin Path. 2008; 129: 540-547.

10. Dixon MF, Genta RM, Yardley JH, et al. Classification and grading of gastritis. The updated Sydney System. International Workshop on the Histopathology of Gastritis, Houston 1994. Am J Surg Pathol. 1996; 20: 1161-1181.

11. Uotani T, Graham Y. Diagnosis of *Helicobacter pylori* using the rapid urease test. Ann Transl Med. 2015; 3: 9.

12. Kirkpatrick LA, Feeney BC. A simple guide to IBM SPSS statistics for version 20.0. Student ed. Belmont, Calif.: Wadsworth Cengage Learning. 2013.

13. Daugirdas J. Chronic hemodialysis prescription. In: Daugirdas JT, Blake PG, Ing TS (eds). Handbook of dialysis. 4th ed. Sydney: Lippincott Williams & Wilkins; 2007:146-69.

14. Devrajani B, Shah S, Soomro A, et al. Type 2 diabetes mellitus: A risk factor for *Helicobacter pylori* infection: A hospital based case-control study. Int J Diabetes Dev Ctries. 2010; 30: 22-26.

15. de Martel C, Parsonnet J. *Helicobacter pylori* infection and gender: A meta-analysis of population-based prevalence surveys. Dig Dis Sci. 2006; 51: 2292-2301.

16. Perdichizzi G, Bottari M, Pallio S, et al. Gastric infection by *Helicobacter pylori* and antral gastritis in hyperglycemic obese and in diabetic subjects. New Microbiol. 1996; 19: 149-154.

17. Zafar KS, Ram V, Kumar M, et al. A study of *Helicobacter pylori* infection in diabetes mellitus. International Journal of Research in Medical Sciences. 2016; 4: 4166-4171.

18. Chen Y and Blaser M. Association Between Gastric *Helicobacter pylori* Colonization and Glycated Hemoglobin Levels. J Infect Dis. 2012; 205: 1195-1202.

19. Demir M, Gokturk HS, Ozturk NA, et al. *Helicobacter pylori* prevalence in diabetes mellitus patients with dyspeptic symptoms and its relationship to glycemic control and late complications. Dig Dis Sci. 2008; 53: 2646-2649.

20. Hsieh MC, Wang SS, Hsieh YT, et al. *Helicobacter pylori* infection associated with high HbA1c and type 2 diabetes. Eur J Clin Invest. 2013; 43: 949-956.

21. Ikeda F, Doi Y, Yonemoto K, et al. Hyperglycemia increases risk of gastric cancer posed by *Helicobacter pylori* infection: a population-based cohort study. Gastroenterology. 2009; 136: 1234.

22. Kucukazman M, Yavuz B, Sacikara M, et al. The Relationship Between Updated Sydney System Score and LDL Cholesterol Levels in Patients Infected with *Helicobacter pylori*. Dig Dis Sci. 2009; 54: 604-607.